Actavis launches Gemcitabine on patent expiry in EU markets

The international generic pharmaceuticals company, Actavis Group, has launched the oncology product Gemcitabine in EU markets, at patent expiry. This launch represents a significant milestone in Actavis’ developing hospital business. The pharmacuetical drug Gemcitabine is the first major oncology product to be made available by Actavis on the date of patent ... Read More...

Actavis receives US approval for generic breast cancer drug

Actavis' generic breast cancer drug, Epirubicin Hydrochloride Injection, has been approved for sale in the US by the Food & Drug Administration (FDA). Epirubicin Hydrochloride is now the second oncology drug from Actavis approved in the US following Irinotecan Hydrochloride which was authorised earlier this year. Epirubicin Hydrochloride Injection, the generic ... Read More...